Anterix (ATEX) Cash & Equivalents (2013 - 2026)

Anterix (ATEX) has 14 years of Cash & Equivalents data on file, last reported at $98.5 million in Q1 2026.

• Quarterly Cash & Equivalents rose 107.99% year-over-year to $98.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $98.5 million (up 107.99% YoY) and the FY2026 annual result came in at $98.5 million, up 107.99% from the prior year.
• Cash & Equivalents climbed to $98.5 million in Q1 2026, from $29.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $105.6 million in Q1 2022 to a low of $28.8 million in Q4 2024.
• A 5-year average of $55.4 million and a median of $48.5 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2023 — Cash & Equivalents slumped 66.42% — and 2026, when it surged 107.99%.
• Tracing ATEX's Cash & Equivalents over 5 years: stood at $57.5 million in 2022, then climbed by 7.86% to $62.0 million in 2023, then plunged by 53.58% to $28.8 million in 2024, then advanced by 2.56% to $29.5 million in 2025, then surged by 233.63% to $98.5 million in 2026.
• The last three Cash & Equivalents figures came in at $98.5 million (Q1 2026), $29.5 million (Q4 2025), and $39.1 million (Q3 2025), per Business Quant data.